ISKRA
DEAD

Add to watchlist:

No watchlists yet
View on USPTO

ISKRA Trademark

Serial Number: 79224919

ISKRA is a trademark filed by Obschestvo s ogranichennoi otvetstvennostyu "NAUCHNO-PROIZVODSTVENNAYA FIRMAMATERIA MEDICA HOLDING" on September 6, 2017. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently no longer active.

Owner Contact Info

Trademark Details

Filing Date

September 6, 2017

Registration Date

Not Registered

Goods & Services

Pharmaceutical and veterinary preparations, namely, pharmaceutical preparations for the treatment of psychoorganic syndrome, neuropsychiatrie and psychiatric diseases, nervous system disorders, Alzheimer disease, parkinson disease, vertigo of different origin, cardiovascular diseases, stroke, cerebrovascular stroke, vegetative-vascular dystonia, neurodegenerative diseases, neuroinfections, somatoform autonomic dysfunction, atherosclerosis, attention deficit disorder, diseases followed by abnormal changes in bioelectrical characteristics of the brain, congestive heart failure, hyperpiesis, neuroticism, psychosomatic disease, stress disorders, asthenic syndrome, neurotoxicosis and obesity; pharmaceutical and veterinary preparations for use in the prevention of parasitic infections, inflammation and inflammatory diseases, respiratory and infectious diseases, immunological, fungal infections, viral infections, parainfluenza, adenovirus, respiratory syncytial virus, coronavirus, labially herpes, genital herpes, chicken pox, herpes zoster, infectious mononucleosis, intestinal infections of viral etiology, including calicivirus, adenovirus, coronavirus, rotavirus, enteroviruses, enteroviral and meningococcal meningitis, hemorrhagic fever with renal syndrome, tick-borne encephalitis, bacterial infections, pseudotuberculosis, whooping cough, yersiniosis, pneumonia; pharmaceutical and veterinary preparations for use in the prevention of bacterial complications of viral infections, prevention of super bacterial infection; pharmaceutical preparations, namely, antihistamines; pharmaceutical preparations for the treatment of AIDS/HIV infection; pharmaceutical preparations, namely, psychotropics; pharmaceutical preparations for the treatment of erectile dysfunction, benign prostatic hyperplasia, prostatitis, dysuric disorders, autonomic disturbances of menopause; pharmaceutical preparations for improving digestion and reducing flatulence; pharmaceutical preparations for the treatment of irritable bowel syndrome, functional gastrointestinal disorders; pharmaceutical preparations, namely, anticonvulsants; pharmaceutical preparations, namely, antianxiety preparations; pharmaceutical preparations, namely, cough treatment preparations; pharmaceutical preparations, namely, preparations for the treatment of respiratory tract infection; pharmaceutical preparations for the treatment of rheumatic arthritis, osteoarthrosis, arthropathy, nonspecific ulcerative colitis; pharmaceutical antihypoxic preparations for use in the treatment of respiratory, pulmonary and circulatory diseases; pharmaceutical and veterinary preparations, namely, antioxidants; pharmaceutical nootropic preparations for use in the improvement of cognitive functions, for use in the treatment of memory diseases and disorders; pharmaceutical vasoprotective preparations for use in the treatment of blood disorders, hemorrhoids, varicose veins and vascular diseases; pharmaceutical antihyperglycemic preparations for use in the treatment of elevated levels of glucose in the blood and elevated levels of glycated hemoglobin in the blood; pharmaceutical preparations for the treatment of alcohol and nicotine addiction; homeopathic supplements; food for babies; dietary supplements for humans and animals; capsules sold empty for medicines; cachets for pharmaceutical purposes, namely, flat capsules sold empty for enclosing unpleasant-tasting pharmaceuticals; appetite suppressant pills

Filing History

FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 27, 2019 FINT
FINAL DISPOSITION NOTICE SENT TO IB
Sep 9, 2019 FICS
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Sep 7, 2019 FICR
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 28, 2019 OPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 12, 2019 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 12, 2019 OPNR
ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND
Sep 7, 2018 MAB2
ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Sep 7, 2018 ABN2
REFUSAL PROCESSED BY IB
Feb 16, 2018 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Feb 1, 2018 RFCS
REFUSAL PROCESSED BY MPU
Feb 1, 2018 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jan 25, 2018 RFCR
NON-FINAL ACTION WRITTEN
Jan 24, 2018 CNRT
APPLICATION FILING RECEIPT MAILED
Jan 23, 2018 MAFR
ASSIGNED TO EXAMINER
Jan 17, 2018 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 17, 2018 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 16, 2018 LIMI
SN ASSIGNED FOR SECT 66A APPL FROM IB
Jan 11, 2018 REPR